Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: A retrospective analysis

Anti-Cancer Drugs

Volumn 25, Issue 1, 2014, Pages 101-105

  Eitan, Ram ^a   Fishman, Ami ^b   Meirovitz, Michai ^d   Goldenberg, Hadassah ^e   Amit, Amnon ^f   Koren, Claude ^a   Schneider, Yulia ^h   Rosengarten, Ora ⁱ   Neuman, Avivit ^f   Keren Rosenberg, Shoshanna ^g   Safra, Tamar ^c,j,k  

^a RABIN MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e Naharia Medical Center   (Israel)

^f RAMBAM MEDICAL CENTER   (Israel)

^g TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^h Rebecca Sieff Government Hospital   (Israel)

ⁱ HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

more..

Author keywords

Chemosensitivity; Liposome encapsulated doxorubicin; Recurrent ovarian cancer; Toxicity

Indexed keywords

CA 125 ANTIGEN; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; DRUG EFFICACY; FATIGUE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES;

EID: 84889251208     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000023     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95:S161-S192.
3. Tummala MK, McGuire WP. Recurrent ovarian cancer. Clin Adv Hematol Oncol 2005; 3:723-736. (Pubitemid 41823989)
4. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol 2009; 472:413-437.
5. Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010; 117:152-158.
6. Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005; 68:293-298. (Pubitemid 41160956)
7. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13:726-732.
8. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000; 78:369-372.
9. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15:987-993. (Pubitemid 27106281)
10. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxelrefractory epithelial ovarian cancer. J Clin Oncol 2000; 18:3093-3100.
11. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-3322. (Pubitemid 32642183)
12. Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 2007; 18:716-721. (Pubitemid 46523276)
13. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15:3185-3191. (Pubitemid 27419330)
14. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposomeencapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94:25-36. (Pubitemid 34049039)
15. Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004; 15:1527-1534. (Pubitemid 39409744)
16. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposomeencapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454. (Pubitemid 32202552)
17. Angioli R, Palaia I, Calcagno M, Manci N, Zullo MA, Bellati F, et al. Liposomeencapsulated doxorubicin citrate in previously treated recurrent/metastatic gynecological malignancies. Int J Gynecol Cancer 2007; 17:88-93. (Pubitemid 46213975)
18. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21:187s-193s.
19. Safra T, Berman T, Yachnin A, Bruchim I, Meirovitz M, Barak F, et al. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study - the Israeli experience. Int J Gynecol Cancer 2013; 23:475-480.